The PROPPR trial was the first large multicenter RCT testing whether a 1:1:1 ratio of plasma, platelets, and RBCs improves survival in severely injured patients requiring massive transfusion. It randomized 680 patients across 12 Level I trauma centers to 1:1:1 vs 1:1:2 ratios and measured 24-hour and 30-day mortality as primary outcomes.
For decades, massively bleeding trauma patients received crystalloid-heavy resuscitation with blood products added reactively based on lab values. Prior observational data (including the PROMMTT study) suggested balanced ratios improved early survival, but no RCT had confirmed this.
When a trauma patient is hemorrhaging and predicted to need massive transfusion, activate your 1:1:1 massive transfusion protocol immediately. Do not wait for labs. The survival benefit is concentrated in the first 2-3 hours — that is when exsanguination kills, and that is when balanced ratios matter most.
Once hemorrhage is controlled, transition to laboratory-guided (goal-directed) resuscitation. The PROPPR data show that continuing to transfuse empirically after hemostasis adds product volume without benefit.
The safety concern that drove reluctance to adopt 1:1:1 — that high plasma and platelet loads would cause ARDS, MOF, and VTE — was directly refuted. With 680 patients and 23 tracked complications, no safety signal emerged.
The PROPPR trial was the first large multicenter RCT testing whether a 1:1:1 ratio of plasma, platelets, and RBCs improves survival in severely injured patients requiring massive transfusion. It randomized 680 patients across 12 Level I trauma centers to 1:1:1 vs 1:1:2 ratios and measured 24-hour and 30-day mortality as primary outcomes.
For decades, massively bleeding trauma patients received crystalloid-heavy resuscitation with blood products added reactively based on lab values. Prior observational data (including the PROMMTT study) suggested balanced ratios improved early survival, but no RCT had confirmed this.
When a trauma patient is hemorrhaging and predicted to need massive transfusion, activate your 1:1:1 massive transfusion protocol immediately. Do not wait for labs. The survival benefit is concentrated in the first 2-3 hours — that is when exsanguination kills, and that is when balanced ratios matter most.
Once hemorrhage is controlled, transition to laboratory-guided (goal-directed) resuscitation. The PROPPR data show that continuing to transfuse empirically after hemostasis adds product volume without benefit.
The safety concern that drove reluctance to adopt 1:1:1 — that high plasma and platelet loads would cause ARDS, MOF, and VTE — was directly refuted. With 680 patients and 23 tracked complications, no safety signal emerged.